科创板首家创新药企业微芯生物产品西达本胺正与全球明星抗癌药进行"头对头"全球黑色素瘤三期临床 试验；首家公有云科创板上市公司优刻得已为全球多个国家提供自主可控的高性能AI算力服务……科 创板开市六年来，越来越多的科创板上市公司携自主可控的核心技术"扬帆出海"，在全球市场掀起一 股"中国硬科技"浪潮。 数据显示，2024年，科创板公司境外收入合计4303.61亿元人民币，同比增长6.1%；173家公司境外收入 同比增长超过30%，63家公司产品远销50个以上国家或地区。高附加值产品在全球市场加速渗透，58家 公司参与制定国际标准，10家创新药企业通过对外授权形式将创新药海外权益授予境外企业，在技术领 域输出全球影响力。 深圳微芯生物科技股份有限公司副总经理海鸥表示，公司基于全球竞争力的原创管线布局，正是科创板 六年赋能的关键成果。在她看来，科创板创新药公司出海呈现两大特点：一是模式多元化，包括自主出 海、授权合作等多种方式；二是技术具备领先性，科创板企业专注于研发First-in-Class(首创新药)或 Best-in-Class(同类最佳)药物。 优刻得科技股份有限公司高级副总裁周可则亲历企业从"云服务出海 ...

统计显示，成交金额最多的是海天瑞声，共有9笔大宗交易，合计成交量为38.30万股，成交金额合计 3830.00万元；其次是光云科技、富创精密，今日大宗交易金额分别为2491.62万元、2093.60万元。 证券时报·数据宝统计显示，7月18日共有16只科创板股发生大宗交易，合计成交31笔，累计成交量 483.67万股，成交额合计1.71亿元。 16只科创板股大宗交易平台今日发生交易，合计成交1.71亿元。 | 代码 | 简称 | 成交笔 | 大宗交易数量 | 平均成交价格 | 相对收盘价折溢价 | 大宗交易金额 | | --- | --- | --- | --- | --- | --- | --- | | | | 数 | （万股） | （元） | （%） | （万元） | | 688787 | 海天瑞 声 | 9 | 38.30 | 100.00 | -14.75 | 3830.00 | | 688365 | 光云科 技 | 7 | 172.43 | 14.45 | -14.95 | 2491.62 | | 688409 | 富创精 | 2 | 40.00 | 52.34 | -0.49 | 2093.60 ...

Group 1 - Chinese assets are experiencing a resurgence, with NIO and Li Auto rising nearly 7% as foreign investment increases in A-shares [2] - The Invesco Global Sovereign Asset Management Research indicates a noticeable recovery in interest from international investment institutions towards the Chinese market, managing approximately $27 trillion in assets [2] - Several foreign institutions express optimism about Chinese assets due to the stable economic performance, policy benefits, and improved corporate earnings outlook [2] Group 2 - The U.S. House of Representatives has advanced cryptocurrency legislation, supported by President Trump, which has led to significant stock price increases for companies in the crypto sector [3] - Blue Ocean Interactive surged over 45% after announcing the establishment of LK Crypto, focusing on mainstream crypto asset management and RWA [3] - Hong Kong is actively developing stablecoin products, creating a dual regulatory framework that connects the U.S. dollar stablecoin with the mainland [3] Group 3 - The Hong Kong IPO market is witnessing a surge, with a significant increase in financing amounts, reflecting global capital's confidence in China's industrial upgrade and consumption potential [7] - On July 9, the Hong Kong Stock Exchange saw five companies queueing for listing in a single day, raising over 10 billion HKD [7] Group 4 - The domestic consumption and investment policies are being emphasized by the Chinese government to strengthen the domestic circulation [5][6] - Analysts highlight the urgency and necessity of promoting consumption as a core strategy for economic growth [6] Group 5 - The A-share market has seen an increase in financing balance for eight consecutive days, totaling an increase of 44.038 billion CNY, indicating positive market sentiment [10] - Analysts suggest that the current macro environment and market risk appetite signal potential for further market growth [10] Group 6 - The number of private equity MOM products registered this year has reached a new high, with 43 products registered by July 15, surpassing the total for the past nine years [14] - This trend indicates a strong interest in the MOM fund model, which allows for diversified asset management [14] Group 7 - The beverage brand Wahaha is facing a decline in sales following a family dispute involving its chairman, which has raised concerns among distributors [16] - The internal family conflict could potentially disrupt the competitive landscape of the Chinese beverage industry [16] Group 8 - The domestic electric vehicle market is seeing significant growth, with L2-level assisted driving penetration exceeding 50% [18] - The heavy truck sales in the first half of the year have increased by approximately 7%, with new energy heavy trucks being a major highlight [18] Group 9 - The stock market is experiencing fluctuations, with the Shanghai Composite Index slightly declining by 0.03% to 3503.78 points [19] - The Hong Kong market is also showing mixed performance, with the Hang Seng Index and the Hang Seng Tech Index experiencing slight declines and gains, respectively [19] Group 10 - The U.S. stock market has seen gains driven by positive economic data and corporate earnings reports, with the S&P 500 rising by 0.45% [20] - Approximately 88% of S&P 500 companies that have reported earnings exceeded analyst expectations, boosting investor confidence [20] Group 11 - Several foreign investment banks have expressed positive views on the Chinese market, with Citigroup raising its ratings for Chinese and Korean markets to "overweight" [21] - Citigroup projects the Hang Seng Index to reach 25,000 points by the end of the year and the CSI 300 Index to reach 4,200 points [21] Group 12 - The stock market's investment logic is shifting towards cash flow analysis in a low-interest-rate environment, with a focus on high-dividend and strong cash flow companies [22] - Analysts are optimistic about sectors such as automotive, electronics, and traditional high-growth areas like AI and pharmaceuticals [22]

Group 1: US Market Performance - Strong retail sales data and a decrease in initial jobless claims led to a rise in the US dollar and stock market, with the S&P 500 and Nasdaq closing at new highs [1][2] - The S&P 500 index rose by 0.54%, the Dow Jones increased by 0.52%, and the Nasdaq gained 0.74% [2] Group 2: Company Earnings and Stock Movements - Netflix's stock dropped by 2% after its earnings report, while PepsiCo's shares rose by 7.4% [3] - Microsoft and Nvidia both saw approximately 1% increases in their stock prices [3] - TSMC reported better-than-expected earnings, with its ADR rising by 3.38%, marking three consecutive days at historical highs [3] Group 3: Bond and Commodity Markets - The 2-year US Treasury yield rose by over 3 basis points, while the dollar appreciated by 0.33% [4] - Gold prices fell by over 1.1% before rebounding, ultimately closing down by 0.28% [5] - Oil prices initially dropped but later increased, with US crude rising nearly 2% from its daily low [5] Group 4: AI and Technology Developments - Nvidia's VP announced plans to port CUDA to the RISC-V architecture, indicating strong demand for AI chips [12][16] - TSMC's Q2 net profit surged by 61%, exceeding expectations, with a projected sales growth of about 30% for the year [12] Group 5: Investment Strategies and Market Trends - Dongfang Securities noted that the Shanghai Composite Index has remained above 3500 points for six trading days, indicating a potential upward trend in the market [13] - The technology sector, particularly AI, robotics, and semiconductors, is expected to remain a long-term focus for investors [13] Group 6: Industry-Specific Developments - Chongqing issued a plan to cultivate the recycling industry for new energy vehicle batteries, aiming for a 90% coverage rate by 2027 [9] - Shanghai's health departments released guidelines to promote the transformation of scientific achievements in medical institutions [10] Group 7: New Financial Products - Huaxia Fund (Hong Kong) launched two tokenized money market funds, including the world's first RMB tokenized fund [11]

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 微芯生物预计上半年净利润3006万元 7月17日，微芯生物(688321.SH)公告称，预计2025年半年度归属于母公司所有者的净利润为3006万元， 实现扭亏为盈。报告期因西达本胺新进医保、西格列他钠销售策略优化及"糖肝共管"优势获认可，带动 产品销量大幅增长，第二季度营收和净利润均实现显著增长。 国药现代上半年净利润同比下降6.46% 国家药监局发布《关于医疗器械分类调整有关工作的公告（征求意见稿）》 7月17日，根据国家药监局官网，为进一步优化有关工作要求，国家药监局组织修订了《医疗器械分类 目录动态调整工作程序》，并明确了分类调整后注册备案相关工作要求。现向社会公开征求意见，时间 是2025年7月17日—8月16日。《征求意见稿》提出了医疗器械管理类别调整后注册备案有关要求、由不 作为医疗器械管理调整为按照医疗器械管理产品有关要求、不作为医疗器械管理产品有关要求等内容。 药械审批 悦康药业一注射液获批临床 7月17日，悦康药业(688658.SH)公告称，公司子公司北京悦康科创医药科技股份有限公司、 ...

点评：该产品上市不仅丰富了远大医药的眼科管线，更彰显了其从传统药企向创新药企转型的战略成 效。未来市场表现值得期待，但需关注医保准入和患者接受度等关键因素。 NO.3 中国医药总经理胡慧冬辞任 公司董事会收到董事、总经理胡慧冬的书面辞职报告。因工作调整原因，胡慧冬申请辞去公司董事、董 事会专门委员会委员及总经理职务，并将不再担任公司任何职务。 每经记者｜陈星 每经编辑｜陈俊杰 ｜ 2025年7月18日 星期五 ｜ NO.1 泰格医药出售参股公司持有的礼新医药股权 泰格医药公告称，公司通过泰格股权直接持有礼新医药股权比例为3.41%；通过持有基金等份额穿透后 间接持有礼新医药股权比例为4.58%。礼新医药拟将95.09%股权转让给正大制药投资（北京）集团有限 公司。公司拟同意标的公司的出售安排，配合将泰格股权直接持有的礼新医药全部股权以约3411万美元 转让给买方。本次交易完成后，公司将不再持有礼新医药的股权。 点评：作为CRO龙头企业，泰格医药通过投资+服务模式深度参与创新药企发展，此次退出既实现了投 资收益，也展现了其专业的投后管理能力。 NO.2 远大医药创新眼药首张处方落地 远大医药7月17日晚间公告， ...

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have announced significant developments, including changes in control, asset sales, investments, and performance forecasts, which may present investment opportunities and risks for investors. Group 1: Control Changes and Major Transactions - Helen Piano's actual controllers are planning a change in control, leading to a suspension of trading starting July 18, 2025, for up to two trading days [3] - Tiger Medical is selling 95.09% of its stake in Lixin Pharmaceutical for approximately $34.11 million [4] - ST Lifan announced that its operational situation has not changed significantly despite a stock price fluctuation of 42.54% over two trading days [9] Group 2: Investments and Acquisitions - Sdic plans to invest approximately 509 million yuan in expanding its high-end functional film production capacity [5] - Dongfang Yuhong's subsidiary intends to acquire 100% of Chile's Construmart for about $123 million [6] - Huaitian Thermal Power has been recommended as the owner of a 700,000 kW wind power project, aligning with its investment strategy [7] Group 3: Performance Announcements - Hangzhou Bank reported a net profit of 11.662 billion yuan for the first half of the year, a year-on-year increase of 16.67% [14] - Tuojing Technology expects a net profit increase of 101% to 108% in Q2 2025, driven by new product breakthroughs [15] - Weicheng Bio anticipates a net profit of 30.06 million yuan for the first half of 2025, reversing a loss from the previous year [17] Group 4: Contracts and Strategic Partnerships - State Grid Information won contracts totaling 966 million yuan from the State Grid Corporation [21] - Beizhi Technology signed a contract worth 164 million yuan with a major client [22] - Mould Technology received a project letter of intent for exterior parts with an expected total sales of 2.044 billion yuan [23] Group 5: Shareholding Changes - Huasheng Lithium plans to reduce its shareholding by up to 2.24% [25] - Yutai Micro's shareholder intends to reduce holdings by up to 3% due to personal funding needs [26] - Alter's controlling shareholder plans to reduce holdings by up to 3% [27]

Mergers and Acquisitions - Dongfang Yuhong plans to acquire 100% equity of Chilean building materials retailer Construmart S.A. for approximately $123 million [1] Major Asset Restructuring - Hongming Co. has terminated its plan to acquire 83% equity of Shenzhen Chisu Automation Equipment Co. due to failure to reach a final agreement [2] Performance Disclosure - Sumeida reported a net profit of 646 million yuan for the first half of the year, a year-on-year increase of 12.62%, with total revenue of 55.101 billion yuan, down 1.52% [3] - Jintong Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with total revenue of 6.959 billion yuan, up 5.55% [4] - Microchip Biotech expects a net profit of approximately 30.06 million yuan for the first half of 2025, a year-on-year increase of 173%, with revenue expected to be around 407 million yuan, up 35% [5] Shareholding Changes - Huasheng Lithium plans to reduce its shareholding by up to 2.24%, equating to a maximum of 3.567 million shares [6] - Yutai Micro's shareholder Li Haihua intends to reduce his stake by up to 3%, totaling no more than 2.4 million shares [7] - Hongqiang Co.'s controlling shareholder Liu Lianjun plans to reduce his stake by up to 3%, amounting to no more than 6.3478 million shares [8] Legal Issues - Jintong Ling has been prosecuted for financial fraud and false issuance of stocks, accused of providing false financial data for six consecutive years, resulting in significant investor losses [9][10]

20只科创板股大宗交易平台今日发生交易，合计成交2.45亿元。 证券时报·数据宝统计显示，7月17日共有20只科创板股发生大宗交易，合计成交38笔，累计成交量 745.22万股，成交额合计2.45亿元。 统计显示，成交金额最多的是南模生物，今日大宗交易成交量为155.93万股，成交金额4984.99万元；其 次是九号公司、鸿泉物联，今日大宗交易金额分别为3240.00万元、2221.93万元。 折溢价情况来看，今日出现大宗交易的科创板股中，均为折价成交，大宗交易成交价格相对收盘价折价 率居前的有微芯生物、海天瑞声、国科军工等，折价率分别为15.49%、13.79%、13.13%。 股价表现方面，今日科创50指数上涨0.80%，科创板股中，今日上涨的有458只，占77.76%，今日发生 大宗交易的科创板股平均上涨2.51%，其中，涨幅居前的为利元亨、安杰思、九联科技等，涨幅分别为 8.25%、7.36%、7.05%，跌幅居前的有九号公司、南模生物等，分别下跌1.15%、0.95%。 从参与大宗交易的营业部看，买方或卖方营业部为机构的成交共有11笔，涉及8只股，机构买入金额居 前的为安杰思、九联科技、鸿泉物联等， ...

Corporate Announcements - Helen Piano's actual controllers are planning a change in control, leading to a suspension of trading starting July 18, 2025, for up to 2 trading days [3] - Tiger Med is selling 95.09% of its stake in Lixin Pharmaceutical to Charoen Pokphand Group for approximately $34.11 million [4] - Stik's wholly-owned subsidiary plans to invest about 509 million yuan in expanding high-end functional film production [5] - Oriental Yuhong's wholly-owned subsidiaries intend to acquire 100% of Chile's Construmart for approximately $123 million, which operates around 31 building material supermarkets [6] Performance Reports - Hangzhou Bank reported a net profit of 11.662 billion yuan for the first half of 2025, a year-on-year increase of 16.67% [8] - Tuojing Technology expects a net profit increase of 101% to 108% for Q2 2025, with revenue projected between 1.21 billion to 1.26 billion yuan [9] - Microchip Biotech anticipates a net profit of 30.06 million yuan for H1 2025, reversing a loss from the previous year, driven by increased sales of specific products [10] - Zhongwei Company expects a net profit increase of 31.61% to 41.28% for H1 2025, with revenue around 4.961 billion yuan [12] - Qianyuan Power reported a net profit of 12.7 million yuan for H1 2025, a decrease of 4.54% year-on-year [13] - Xiamen Tungsten's net profit for H1 2025 was 972 million yuan, down 4.41% year-on-year, attributed to the absence of significant investment gains from the previous year [14] Major Contracts - State Grid Information Technology announced winning contracts totaling 966 million yuan from the State Grid Corporation for equipment procurement [16] - Beizhi Technology signed a contract worth 164 million yuan with Jushi Group for equipment procurement [17] - Mould Technology received a project letter for exterior parts from a luxury car client, with expected total sales of 2.044 billion yuan over five years [18] Shareholder Actions - Huasheng Lithium Battery's shareholder plans to reduce holdings by up to 2.24% of the company's total shares [20] - Hongta Securities intends to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 12.76 yuan per share [22]